Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Allogene Therapeutics Inc (NQ: ALLO )

3.510 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10
Open 3.510
Bid (Size) 3.400 (5)
Ask (Size) 3.640 (1)
Prev. Close 3.510
Today's Range 3.510 - 3.510
52wk Range 3.480 - 12.21
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Allogene Therapeutics
Via Benzinga
Allogene Therapeutics Announces Participation in September Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-39.06%
-39.06%
1 Month
-7.14%
-7.14%
3 Month
-25.79%
-25.79%
6 Month
-30.22%
-30.22%
1 Year
-67.74%
-67.74%

More News

Read More
The Next Meme Stock: 6 Tickers Leading a Meme Stock Revival
Via MarketBeat
Allogene Therapeutics Appoints Earl Douglas as General Counsel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Outlook For Allogene Therapeutics
Via Benzinga
Analyst Ratings for Allogene Therapeutics
Via Benzinga
Why Allogene Stock Is Trading Down Today
Via Benzinga
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
3 Stocks With Sky-High Short Interest Levels
Via MarketBeat
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Short Squeeze Alert: The 5 Most Shorted Stocks Right Now
Via InvestorPlace
Where Allogene Therapeutics Stands With Analysts
Via Benzinga
Allogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status
Via Benzinga
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Allogene Therapeutics Announces Departure of Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Stocks to Short in May 2023
Via InvestorPlace
7 Short-Interest Stocks to Target for Explosive Gains
Via InvestorPlace
As Feinstein Returns To Congress, Reports Of Her Stock Profits Upset Aaron Rodgers
Via Benzinga
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.